Biography & Research:
My central goal is to understand the pathophysiology of Alzheimer’s disease (AD) using neuroimaging, cognitive testing, and novel fluid biomarkers. AD represents a complex disease and no one measure provides a thorough characterization of the AD disease trajectory. Instead a multidimensional approach is needed to integrate intersecting measures of biology and cognition. As a neuroscientist I have been trained to integrate behavioral and cognitive testing with AD biomarkers measured using both neuroimaging techniques such as functional magnetic resonance imaging (MRI), structural MRI, and positron emission tomography (PET) as well as fluid biomarkers measured in cerebrospinal fluid (CSF) and blood.